Frontiers in Endocrinology, 2021 The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently approved agent of this drug class, and the only GLP-1RA currently available as both subcutaneous and oral formulation.
Mark M Smits
exaly +5 more sources
Case Report: Semaglutide-associated depression: a report of two cases
Frontiers in Psychiatry, 2023 Semaglutide, as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was approved for glucose control in type 2 diabetes mellitus in 2017 and approved for weight loss in 2021 by the U.S. Food and Drug Administration (FDA). No psychiatric adverse effect
Jia-Rui Li +3 more
exaly +3 more sources
Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes [PDF]
Biomedicines, 2023 Background: Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist. Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) risk by reducing major adverse cardiovascular events in type 2 ...
Angelo Maria Patti +7 more
doaj +3 more sources
Diabetes, Obesity and Metabolism, 2017 AIM: To investigate the mechanism of action for body weight loss with semaglutide. MATERIALS AND METHODS: This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks treatment with once-weekly ...
John E Blundell +2 more
exaly +2 more sources
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis [PDF]
Cardiovascular Diabetology, 2023 Background Semaglutide is a glucose-lowering treatment for type 2 diabetes (T2D) with demonstrated cardiovascular benefits; semaglutide may also have kidney-protective effects.
Peter Rossing +6 more
doaj +2 more sources
The Ethics of Ozempic and Wegovy [PDF]
J Med EthicsSemaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market. Manufactured by Novo Nordisk, semaglutide is the newest in a family of glucagon-like peptide-1 receptor agonists used most commonly ...
Ryan, Nanette, Savulescu, Julian
core +4 more sources
Contractile Effects of Semaglutide in the Human Atrium [PDF]
PharmaceuticsSemaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist. GLP-1R agonists are used to treat type 2 diabetes and obesity. It is currently unknown whether semaglutide can directly increase force of contraction (FOC) in the human heart.
Joachim Neumann +4 more
doaj +3 more sources
Redox BiologyAims: Doxorubicin is a powerful chemotherapeutic agent for cancer, whose use is limited due to its potential cardiotoxicity. Semaglutide (SEMA), a novel analog of glucagon-like peptide-1 (GLP-1), has received widespread attention for the treatment of ...
Chunyu Zeng
exaly +3 more sources
Semaglutide as a Possible Calmodulin Binder: Ligand-Based Computational Analyses and Relevance to Its Associated Reward and Appetitive Behaviour Actions [PDF]
Scientia PharmaceuticaSemaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has gained considerable attention as a therapeutic agent for type 2 diabetes mellitus and obesity.
Giuseppe Floresta +6 more
doaj +4 more sources
Complementary neuroprotective effects of semaglutide and papaya in diabetic encephalopathy via antioxidant and insulin-signaling pathways [PDF]
Scientific ReportsDiabetic encephalopathy is a chronic neurodegenerative complication of diabetes mellitus characterized by cognitive decline, neuroinflammation, oxidative stress, and impaired insulin signaling. Semaglutide, a glucagon-like peptide-1 receptor agonist, has
Mohamed M. Zeweil +11 more
doaj +2 more sources